Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
Date:3/12/2008

e date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue

SVP & Chief Financial Officer

Cadence Pharmaceuticals, Inc.

858-436-1400

Anna Gralinska

Director, Investor Relations

Cadence Pharmaceuticals, Inc.

858-436-1452

CADENCE PHARMACEUTICALS, INC.

(a development stage company)

CONDENSED STATEMENTS OF OPERATIONS

(unaudited)

Three Months Ended Years Ended

December 31, December 31,

2007 2006 2007 2006

Operating expenses:

Research and

development $10,431,529 $7,775,168 $41,781,357 $47,826,761

Marketing 1,403,080 249,490 2,865,804 810,315

General and

administrative 2,767,594 1,615,590 9,586,705 4,946,121

Total operating

expenses 14,602,203 9,640,248 54,233,866 53,583,197

Loss from operations (14,602,203) (9,640,248) (54,233,866) (53,583,197)

Other income (expense):

Interest income 628,570 912,907 3,404,447 1,944,908

Interest expense (261,525) (225,768) (867,524) (497,617)

Other expense 2,326 2,894 (16,611) (37,035)

Total other income,

net 369,371 690,033 2,520,312 1,410,256

Net loss $(14,232,832) $(8,950,215) $(51,713,554) $(52,172,941)

Basic and dilute
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
2. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
3. ISTA Pharmaceuticals to Present at the Cowen & Company 28th Annual Health Care Conference
4. SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results
5. Onyx Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
6. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
7. Drinking Water Association Discusses Pharmaceuticals in Water
8. Genesis Pharmaceuticals Changes Auditors
9. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
11. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... medicine and trauma surgery have had a significant ... immediately after major injuries, including burns. Patients ... now are at greatest risk from infections ... sepsis or from inflammation-induced multiorgan failure. ... (MGH) investigators that measures the movement of key ...
(Date:6/19/2013)... (June 19, 2013) In what is believed to ... most common form of hereditary dystonia a movement ... in deep brain stimulation report good success rates and ... the Movement Disorders Program at Cedars-Sinai Medical Center,s Department ... the Division of Neurosurgery at Beth Israel Deaconess Medical ...
(Date:6/19/2013)... The results of three important studies have been published ... journal of the Congress of Neurological Surgeons . ... & Wilkins , a part of Wolters Kluwer ... learning" using artificial neural networks (ANNs) may improve the ... cancers. Another study in the June Neurosurgery ...
(Date:6/19/2013)... Ann Arbor, Mich. Children had half as ... had evening office hours on five or more days ... experts at C.S. Mott Children,s Hospital and Johns Hopkins ... month in The Journal of Pediatrics and ... , "These findings are an important step in understanding ...
(Date:6/19/2013)... is available in Spanish . ... neglected diseases, it goes by the name of the 10/90 ... devoted to conditions that accounted for 90 per cent of ... that the Drugs for Neglected Diseases initiative (DNDi) came into ... organization has been granted the BBVA Foundation Frontiers of Knowledge ...
Breaking Medicine News(10 mins):Health News:Restoring appropriate movement to immune cells may save seriously burned patients 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5
... as a key resource for finding the best Government and nonprofit ... straightforward and credible information catalogued on the site. But it is ... for disease prevention and wellness information interactive and action oriented. ... ...
... Amoena, the worldwide leader of post-breast surgery ... Hannah Collection, the industry,s first post-surgical garments ... ease discomfort after breast surgery.(Logo: ... http://www.newscom.com/cgi-bin/prnh/20090408/CL96087 )The post-surgical camisole ...
... ORTHOCON¿ Inc. today announced that Paul R. Sohmer, ... Executive Officer. The company also announced the closing of ... healthcare investors. ORTHOCON is developing innovative implantable devices ... platform may be leveraged to deliver a variety of ...
... high marks on intentions for good nutrition but lack ... no surprise that with the current economic conditions, three-quarters ... healthy eating is largely dependent on what food families ... family pantries, fridges, and freezers, Rutgers University ...
... 8 Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) ... BG Medicine (BGM) in its Phase 2 clinical safety ... this collaboration, BGM will measure levels of Galectin-3 in ... for cardiac remodeling associated with advanced stages of heart ...
... April 8 The College of American Pathologists (CAP), ... and deeming authority under the Clinical Laboratory Improvement Amendments ... Services (CMS) since 1995, has been notified that it ... a six-year period, the longest period available for this ...
Cached Medicine News:Health News:healthfinder.gov Adds New Interactive Features to Its Web Site 2Health News:Amoena Introduces First Post Surgical Garments With Vitamin E & Aloe to Help Soothe and Comfort After Breast Surgery 2Health News:ORTHOCON Announces Appointment of New CEO and $25 Million Series B Financing 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 3Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 2Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 3Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 4Health News:CAP Deeming Status Renewed 2
(Date:6/19/2013)... June 19, 2013   NextDocs announced today ... clinical research organization, at DIA 2013 , the ... will present case studies that explore best practices for ... electronic trial master file (eTMF) systems. ... present alongside Krystyna Kowalczyk , executive vice president ...
(Date:6/19/2013)... CLARA, Calif. , June 19, 2013 /PRNewswire/ ... control solutions for life sciences process applications, announced ... glass bioreactors for upstream cell culture and fermentation.  ... a new product family of Finesse bioreactors and ... and cGMP applications.  They are fully compatible with ...
(Date:6/19/2013)... India , June 19, 2013 ... Bureau has recently added DrugPatentWatch to ... ( http://www.bharatbook.com/drugpatentwatch-tour.pdf )      ... provides comprehensive information on pharmaceutical, drug ... information supports the critical business functions ...
Breaking Medicine Technology:NextDocs and Novella to Present on eTMF at DIA 2013 2Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2Drug Patent Watch 2Drug Patent Watch 3
... 13 Otix Global, Inc. (Otix) (Nasdaq: OTIX ... today announced that it has decided to discontinue its operations ... decision, Sam Westover, Chairman and CEO of Otix stated, "the ... stability of our business and, as a result, we have ...
... Applied Precision is sending its Mobile ... and research centers.   The Applied Precision ... 40-foot coach bus.  The lab is equipped with Applied ... a wet lab.  New this year is a special ...
Cached Medicine Technology:Otix Global, Inc. to Discontinue German Operations 2Otix Global, Inc. to Discontinue German Operations 3Applied Precision's Mobile Imaging Lab Hits the Road for a Cross-Country Journey 2
... more efficient way to control thermoregulation. ... operated patient warming system, provides hospitals, ... a compact and better way to ... process. Its unique design combines functionality ...
... WarmAir® system from CSZ safely provides effective ... of the unique patented design of our ... lower velocity blower which supplies gently moving, ... that may spread contaminants to your patient ...
Since 1964, in its plants of Sesto Fiorentino, Sbisà produces a wide and qualified range of instruments for ophthalmology and optometry....
Inquire...
Medicine Products: